VMAC Meeting to Consider AquAdvantage Salmon

AquaBounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, announces progress on its pending New Animal Drug Application for AquAdvantage Salmon from the U.S. Food and Drug Administration ("FDA"), reports www.megafishnet.com with reference to AquaBounty Technologies, Inc.

The Company confirms that it has been informed by the Center for Veterinary Medicine of the FDA of its intention to discuss and make a recommendation regarding the approval of the pending application for AquaBounty's AquAdvantage® Salmon at a meeting of the Veterinary Medicine Advisory Committee ("VMAC" or "the Committee"). The meeting has been scheduled for 19-20 September 2010 and is to be held at the Rockville Hilton, 1750 Rockville Pike, Rockville, Maryland. In addition, the FDA will hold a public hearing on the application of its food labeling requirements and how they might apply to AquAdvantage Salmon on 21 September at the same location.

The VMAC advises the Office of the Commissioner of the FDA in discharging its responsibilities as they relate to assuring safe and effective products over which the agency has regulatory responsibility. The Committee reviews and evaluates available data concerning the safety and effectiveness of the product in question and makes appropriate recommendations to the Commissioner.

Dr. Ronald Stotish, President and CEO of AquaBounty, commented: "This is welcome and exciting news for the Company as we near the end of the detailed and necessary process to receive regulatory approval for our AquAdvantage® Salmon. The meeting will provide an opportunity for the public to understand how the application of our technology will enable the safe and sustainable production of high quality fish. We believe the economic and environmental benefits of our salmon will very effectively help to meet the demand for food from the growing world population."